FDA
-
-
-
-
-
-
-
Ocugen Provides Business Update with First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
-
-
-
-
-
-
-
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
-
-
-
-
-
-
-
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
-
-
-
-
-
-
-
Ocugen (OCGN) Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for OCU400
-
-
-
-
-
-
-
Ocugen (OCGN) Reports Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
-
329,910 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

